Kevin Schutz, PharmD

Kevin Schutz, PharmD has over 18 years of experience in the pharmaceutical industry. Kevin began their career in 2002 as a Scientific Director at Ingenix. Kevin then moved to Embryon in 2003, where they held the same role. In 2006, they joined Esprit Pharma as an Associate Director of CME and Publications. In 2008, they became an Associate Director of Regulatory Affairs at EKR Therapeutics, which was later acquired by Cornerstone Therapeutics. Kevin then moved to Ipsen in 2012, where they were an Associate Director of Regulatory Affairs. That same year, they joined Amarin Corporation as a Director of Regulatory Affairs. In 2014, they became Senior Director of Regulatory Affairs at Insmed. In 2019, they joined Osmotica Pharmaceutical Corp. as a Regulatory Affairs professional. In 2021, they were appointed VP of Regulatory Affairs at Tiziana Life Sciences. Most recently, they were appointed Vice President of Regulatory Affairs at CinCor Pharma, Inc. in 2022.

Kevin Schutz, PharmD, obtained their PharmD degree from the University of the Sciences in Philadelphia between 1995 and 2001. Kevin then attended Seton Hall University School of Law in 2011, where they obtained a Healthcare Compliance Certification Program and an Online Graduate Certificate in Pharmaceutical & Medical Device Law & Compliance.